Suppr超能文献

肺动脉压对重度慢性阻塞性肺疾病运动功能的影响

Impact of pulmonary artery pressure on exercise function in severe COPD.

作者信息

Sims Michael W, Margolis David J, Localio A Russell, Panettieri Reynold A, Kawut Steven M, Christie Jason D

机构信息

Pulmonary, Allergy, and Critical Care Division, Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA; Airways Biology Initiative, Department of Medicine, and the Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA.

Airways Biology Initiative, Department of Medicine, and the Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA.

出版信息

Chest. 2009 Aug;136(2):412-419. doi: 10.1378/chest.08-2739. Epub 2009 Mar 24.

Abstract

BACKGROUND

Although pulmonary hypertension commonly complicates COPD, the functional consequences of increased pulmonary artery pressures in patients with this condition remain poorly defined.

METHODS

We conducted a cross-sectional analysis of a cohort of 362 patients with severe COPD who were evaluated for lung transplantation. Patients with pulmonary hemodynamics measured by cardiac catheterization and available 6-min walk test results were included. The association of mean pulmonary artery pressure (mPAP) with pulmonary function, echocardiographic variables, and 6-min walk distance was assessed.

RESULTS

The prevalence of pulmonary hypertension (mPAP, > 25 mm Hg; pulmonary artery occlusion pressure [PAOP], < 16 mm Hg) was 23% (95% confidence interval, 19 to 27%). In bivariate analysis, higher mPAP was associated with lower FVC and FEV(1), higher Pco(2) and lower Po(2) in arterial blood, and more right heart dysfunction. Multivariate analysis demonstrated that higher mPAP was associated with shorter distance walked in 6 min, even after adjustment for age, gender, race, height, weight, FEV(1), and PAOP (-11 m for every 5 mm Hg rise in mPAP; 95% confidence interval, -21 to -0.7; p = 0.04).

CONCLUSIONS

Higher pulmonary artery pressures are associated with reduced exercise function in patients with severe COPD, even after controlling for demographics, anthropomorphics, severity of airflow obstruction, and PAOP. Whether treatments aimed at lowering pulmonary artery pressures may improve clinical outcomes in COPD, however, remains unknown.

摘要

背景

虽然肺动脉高压常使慢性阻塞性肺疾病(COPD)病情复杂化,但这种情况下肺动脉压力升高的功能后果仍未明确界定。

方法

我们对362例接受肺移植评估的重度COPD患者队列进行了横断面分析。纳入通过心导管检查测量肺血流动力学且有可用6分钟步行试验结果的患者。评估平均肺动脉压(mPAP)与肺功能、超声心动图变量及6分钟步行距离之间的关联。

结果

肺动脉高压(mPAP>25mmHg;肺动脉闭塞压[PAOP]<16mmHg)的患病率为23%(95%置信区间为19%至27%)。在双变量分析中,较高的mPAP与较低的用力肺活量(FVC)和第1秒用力呼气容积(FEV₁)、动脉血中较高的二氧化碳分压(Pco₂)和较低的氧分压(Po₂)以及更严重的右心功能不全相关。多变量分析表明,即使在调整年龄、性别、种族、身高、体重、FEV₁和PAOP后,较高的mPAP仍与6分钟内步行距离较短相关(mPAP每升高5mmHg,步行距离缩短11m;95%置信区间为-21至-0.7;p = 0.04)。

结论

即使在控制了人口统计学、人体测量学、气流阻塞严重程度和PAOP之后,重度COPD患者中较高的肺动脉压力仍与运动功能降低相关。然而,旨在降低肺动脉压力的治疗是否能改善COPD的临床结局仍不清楚。

相似文献

1
Impact of pulmonary artery pressure on exercise function in severe COPD.
Chest. 2009 Aug;136(2):412-419. doi: 10.1378/chest.08-2739. Epub 2009 Mar 24.
2
Exercise capacity in COPD patients with exercise-induced pulmonary hypertension.
Int J Chron Obstruct Pulmon Dis. 2018 Oct 31;13:3599-3610. doi: 10.2147/COPD.S161175. eCollection 2018.
3
Characterization of patients with borderline pulmonary arterial pressure.
Chest. 2014 Dec;146(6):1486-1493. doi: 10.1378/chest.14-0194.
5
Aerobic exercise capacity in COPD patients with and without pulmonary hypertension.
Respir Med. 2010 Jan;104(1):121-6. doi: 10.1016/j.rmed.2009.06.006. Epub 2009 Jul 3.
6
Pulmonary hemodynamic profile in chronic obstructive pulmonary disease.
Int J Chron Obstruct Pulmon Dis. 2015 Jul 14;10:1313-20. doi: 10.2147/COPD.S78180. eCollection 2015.
7
Pulmonary hypertension in chronic lung diseases.
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D109-16. doi: 10.1016/j.jacc.2013.10.036.
8
Pulmonary artery to aorta ratio is associated with cardiac structure and functional changes in mild-to-moderate COPD.
Int J Chron Obstruct Pulmon Dis. 2017 May 12;12:1439-1446. doi: 10.2147/COPD.S131413. eCollection 2017.
9

引用本文的文献

4
Long-Term Outcome of Chronic Obstructive Pulmonary Disease: A Review.
Tuberc Respir Dis (Seoul). 2022 Oct;85(4):289-301. doi: 10.4046/trd.2022.0074. Epub 2022 Jul 13.
5
The Incidence and Prevalence of Pulmonary Hypertension in the COPD Population: A Systematic Review and Meta-Analysis.
Int J Chron Obstruct Pulmon Dis. 2022 Jun 10;17:1365-1379. doi: 10.2147/COPD.S359873. eCollection 2022.
6
Relevance of Cor Pulmonale in COPD With and Without Pulmonary Hypertension: A Retrospective Cohort Study.
Front Cardiovasc Med. 2022 Feb 16;9:826369. doi: 10.3389/fcvm.2022.826369. eCollection 2022.
7
Diffusing capacity in chronic obstructive pulmonary disease assessment: A meta-analysis.
Chron Respir Dis. 2021 Jan-Dec;18:14799731211056340. doi: 10.1177/14799731211056340.
8
High-intensity interval training and pulmonary hemodynamics in COPD with hypoxemia.
Eur Clin Respir J. 2021 Oct 11;8(1):1984642. doi: 10.1080/20018525.2021.1984642. eCollection 2021.
9
Main pulmonary artery enlargement predicts 90-day readmissions in Chinese COPD patients.
J Thorac Dis. 2021 Oct;13(10):5731-5740. doi: 10.21037/jtd-21-344.
10
Chronic Obstructive Pulmonary Disease and the Cardiovascular System: Vascular Repair and Regeneration as a Therapeutic Target.
Front Cardiovasc Med. 2021 Apr 12;8:649512. doi: 10.3389/fcvm.2021.649512. eCollection 2021.

本文引用的文献

1
Pulmonary hypertension in COPD.
Eur Respir J. 2008 Nov;32(5):1371-85. doi: 10.1183/09031936.00015608.
2
Cardiac disease in chronic obstructive pulmonary disease.
Proc Am Thorac Soc. 2008 May 1;5(4):543-8. doi: 10.1513/pats.200708-142ET.
3
A randomised, controlled trial of bosentan in severe COPD.
Eur Respir J. 2008 Sep;32(3):619-28. doi: 10.1183/09031936.00011308. Epub 2008 Apr 30.
4
Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD.
Pulm Pharmacol Ther. 2008;21(3):558-64. doi: 10.1016/j.pupt.2008.01.012. Epub 2008 Feb 8.
5
Sildenafil treatment in COPD does not affect stroke volume or exercise capacity.
Eur Respir J. 2008 Apr;31(4):759-64. doi: 10.1183/09031936.00114207. Epub 2007 Dec 19.
6
7
Skeletal muscle dysfunction in patients with idiopathic pulmonary arterial hypertension.
Respir Med. 2007 Nov;101(11):2366-9. doi: 10.1016/j.rmed.2007.06.014. Epub 2007 Aug 6.
8
The 6-min walk distance: change over time and value as a predictor of survival in severe COPD.
Eur Respir J. 2004 Jan;23(1):28-33. doi: 10.1183/09031936.03.00034603.
9
Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease.
Am J Respir Crit Care Med. 2003 Mar 1;167(5):735-40. doi: 10.1164/rccm.200210-1130OC. Epub 2002 Dec 12.
10
Hemodynamic characterization of patients with severe emphysema.
Am J Respir Crit Care Med. 2002 Aug 1;166(3):314-22. doi: 10.1164/rccm.2107027.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验